Icosavax Raises $100m To Take RSV, COVID-19 Vaccines Into The Clinic

Platform Enables Vaccines Based On Non-Naturally Occurring VLPs

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The company doubled its series A total of $51m to not only test its coronavirus and RSV candidates, but to also advance a vaccine targeting both RSV and hMPV for pneumonia prevention in elderly adults.

Vaccine vial dose
Icosavax's first vaccines aim to prevent COVID-19 and pneumonia • Source: Shutterstock

Icosavax, Inc. advanced its virus-like particle (VLP) technology platform for the creation of novel vaccines that prevent respiratory diseases and scaled up manufacturing to support clinical trials with $51m in series A venture capital it raised in 2019. The company also developed a candidate for the prevention of COVID-19, which received $16.5m in early funding commitments late last year, and now it has raised a $100m series B round to take its vaccine against SARS-CoV-2 and its other lead vaccine candidate for respiratory syncytial virus (RSV) into clinical trials in 2021.

Seattle-based Icosavax, which announced its new funding on 7 April, launched in October 2019 to develop vaccines based on computationally...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

spo

Akash test for clone

Test article to check the clone issue

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.